Cargando…

Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment

BACKGROUND: (18)F-florbetaben (FBB) positron emission tomography (PET) scan has been widely used in research and routine clinical practice. Most studies used late-phase (scanning from 90 to 110 min after injection) FBB scans to generate beta-amyloid accumulation data. The feasibility of middle-phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Cheng-Han, Lu, Yueh-Hsun, Lee, Tse-Hao, Tu, Chun-Yuan, Fuh, Jong-Ling, Wang, Yuh-Feng, Yang, Bang-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423384/
https://www.ncbi.nlm.nih.gov/pubmed/37581034
http://dx.doi.org/10.21037/qims-23-58
_version_ 1785089437951066112
author Wu, Cheng-Han
Lu, Yueh-Hsun
Lee, Tse-Hao
Tu, Chun-Yuan
Fuh, Jong-Ling
Wang, Yuh-Feng
Yang, Bang-Hung
author_facet Wu, Cheng-Han
Lu, Yueh-Hsun
Lee, Tse-Hao
Tu, Chun-Yuan
Fuh, Jong-Ling
Wang, Yuh-Feng
Yang, Bang-Hung
author_sort Wu, Cheng-Han
collection PubMed
description BACKGROUND: (18)F-florbetaben (FBB) positron emission tomography (PET) scan has been widely used in research and routine clinical practice. Most studies used late-phase (scanning from 90 to 110 min after injection) FBB scans to generate beta-amyloid accumulation data. The feasibility of middle-phase scan is seldom discussed. Using the middle-phase data can shorten the patients’ waiting between the injection and scan, and hospital can acquire more flexible schedule of routine scan. METHODS: Paired middle-phase (60–80 min) FBB scans and standard (90–110 min) FBB scans were obtained from 27 subjects (12 neurodegenerative dementia, 8 mild cognitive impairment, 3 normal control, and 4 patients not suffering from neurodegenerative dementia). Standardized uptake value ratios (SUVRs) were calculated and converted to centiloid (CL) scale to investigate the impact on image quantification. CL pipeline validation were performed to build an equation converting the middle-phase data into equivalent standard scans. Cohen’s kappa of binary interpretation and brain amyloid plaque load (BAPL) score were also used to evaluate the intrareader agreement of the FBB image from the two protocols. RESULTS: The middle-phase FBB SUVR showed an excellent correlation, which provided a linear regression equation of SUVR(FBB60–80) = 0.88 × SUVR(FBB90–110) + 0.07, with R(2)=0.98. The slope of the equation indicated that there was bias between the middle and standard acquisition. This can be converted into the CL scale using CL = 174.68 × SUVR − 166.39. Cohen’s kappa of binary interpretation and BAPL score were 1.0 (P<0.0001). CONCLUSIONS: Our findings indicate that the middle-phase FBB protocol is feasible in clinical applications for scans that are at either end of beta-amyloid spectrum, which provides comparable semiquantitative results to standard scan. Patient’s waiting time between the injection and scan can be shortened.
format Online
Article
Text
id pubmed-10423384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-104233842023-08-14 Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment Wu, Cheng-Han Lu, Yueh-Hsun Lee, Tse-Hao Tu, Chun-Yuan Fuh, Jong-Ling Wang, Yuh-Feng Yang, Bang-Hung Quant Imaging Med Surg Original Article BACKGROUND: (18)F-florbetaben (FBB) positron emission tomography (PET) scan has been widely used in research and routine clinical practice. Most studies used late-phase (scanning from 90 to 110 min after injection) FBB scans to generate beta-amyloid accumulation data. The feasibility of middle-phase scan is seldom discussed. Using the middle-phase data can shorten the patients’ waiting between the injection and scan, and hospital can acquire more flexible schedule of routine scan. METHODS: Paired middle-phase (60–80 min) FBB scans and standard (90–110 min) FBB scans were obtained from 27 subjects (12 neurodegenerative dementia, 8 mild cognitive impairment, 3 normal control, and 4 patients not suffering from neurodegenerative dementia). Standardized uptake value ratios (SUVRs) were calculated and converted to centiloid (CL) scale to investigate the impact on image quantification. CL pipeline validation were performed to build an equation converting the middle-phase data into equivalent standard scans. Cohen’s kappa of binary interpretation and brain amyloid plaque load (BAPL) score were also used to evaluate the intrareader agreement of the FBB image from the two protocols. RESULTS: The middle-phase FBB SUVR showed an excellent correlation, which provided a linear regression equation of SUVR(FBB60–80) = 0.88 × SUVR(FBB90–110) + 0.07, with R(2)=0.98. The slope of the equation indicated that there was bias between the middle and standard acquisition. This can be converted into the CL scale using CL = 174.68 × SUVR − 166.39. Cohen’s kappa of binary interpretation and BAPL score were 1.0 (P<0.0001). CONCLUSIONS: Our findings indicate that the middle-phase FBB protocol is feasible in clinical applications for scans that are at either end of beta-amyloid spectrum, which provides comparable semiquantitative results to standard scan. Patient’s waiting time between the injection and scan can be shortened. AME Publishing Company 2023-06-14 2023-08-01 /pmc/articles/PMC10423384/ /pubmed/37581034 http://dx.doi.org/10.21037/qims-23-58 Text en 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wu, Cheng-Han
Lu, Yueh-Hsun
Lee, Tse-Hao
Tu, Chun-Yuan
Fuh, Jong-Ling
Wang, Yuh-Feng
Yang, Bang-Hung
Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title_full Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title_fullStr Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title_full_unstemmed Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title_short Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
title_sort feasibility evaluation of middle-phase (18)f-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423384/
https://www.ncbi.nlm.nih.gov/pubmed/37581034
http://dx.doi.org/10.21037/qims-23-58
work_keys_str_mv AT wuchenghan feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT luyuehhsun feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT leetsehao feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT tuchunyuan feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT fuhjongling feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT wangyuhfeng feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment
AT yangbanghung feasibilityevaluationofmiddlephase18fflorbetabenpositronemissiontomographyimagingusingcentiloidquantificationandvisualassessment